Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
New Delhi: Indian public health campaigners on Wednesday said they will oppose the patent applications of a promising new but ...
Lencapavir, which is dosed only every six months, is highly effective at preventing HIV, but advocates worry its cost will blunt its impact.
Drugmaker Gilead has announced that its new, twice-a-year shot ... approval from the U.S. Food and Drug Administration (FDA) to market lenacapavir as an HIV treatment. “With such remarkable ...
"It is crucial that Dr. Mezher retracts the incorrect claims from his TikTok." The post Viral Pic Of Bloody Toilet Paper ...
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients ... Only two patients who received the drug—approved for treating HIV—contracted the ...
Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...
The HIV drug which costs around $44,000 for twice-yearly ... Worldwide there are 1.3 million infections every year, with one new HIV infection every 24 seconds. Gilead has several patent ...
Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of ...